Interstitial Lung Disease Day on Sept. 16 aims to provide educational information and raise awareness, writes columnist Sam Kirton.

The FDA will decide by early next year whether to expand use of an approved inhaled therapy for lung disease to include ...

September is Pulmonary Fibrosis Awareness Month, and advocates around the globe are joining together to shine a light on PF ...

Tell us a little about yourself and your experience with pulmonary fibrosis. Your answers help us share information, resources, and community content that are more relevant to you. It only takes about ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but in people who develop lung fibrosis after a severe COVID-19 infection, ...

A new type of pericyte called Peri2 is linked to scar tissue formation in the lungs of people with pulmonary fibrosis (PF), according to a study. Pericytes are cells that surround blood vessels. A ...

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

Living with a chronic and progressive disease like pulmonary fibrosis (PF) can be challenging, and there are many issues a person with PF needs to consider, including lifestyle changes, coping with ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...